

AMENDMENT

Kindly amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.


IN THE CLAIMS:

Kindly amend the claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, to read as follows:

1-66. (Cancelled)

67. (Currently amended) A method of inhibiting steroid sulphatase activity comprising administering, a non-oestrogenic sulphamate compound suitable for use as an inhibitor of oestrone sulphatase to a patient in need of inhibition of steroid sulphatase activity by a non-oestrogenic sulphamate compound lacking oestrogenic activity, wherein the non-oestrogenic sulphamate compound is a sulphamate compound having Formula IV;

Formula IV



wherein


one of R₁ and R₂ is H and the other of R₁ and R₂ is a substituent other than H or R₁ and R₂ may be the same or different but not both being H, wherein the substituent other than H is alkyl, cycloalkyl, alkoxy, alkenyl, aryl, substituted alkyl, substituted cycloalkyl, substituted alkenyl, substituted aryl, a nitrogen containing group, a S containing group, or a carboxy containing group;

wherein Y is a suitable linking group comprising one or more of C, O, N, and S; and

each of R₃ and R₄ is independently selected from H, alkyl, cycloalkyl, alkenyl and aryl, wherein at least one of R₃ and R₄ is H.

68. (Currently amended) A method of treating endocrine-dependent cancer comprising administering a non-oestrogenic sulphamate compound suitable for use as an inhibitor of oestrone sulphatase, to a patient in need of treatment of endocrine-dependent cancer by a non-oestrogenic sulphamate compound lacking oestrogenic activity, wherein the compound is a sulphamate compound having Formula IV;

Formula IV



wherein

one of R₁ and R₂ is H and the other of R₁ and R₂ is a substituent other than H or R₁ and R₂ may be the same or different but not both being H, wherein the substituent other than H is alkyl, cycloalkyl, alkoxy, alkenyl, aryl, substituted alkyl, substituted cycloalkyl, substituted alkenyl, substituted aryl, a nitrogen containing group, a S containing group, or a carboxy containing group;

Y is a suitable linking group comprising one or more of C, O, N, and S; and

each of R₃ and R₄ is independently selected from H, alkyl, cycloalkyl, alkenyl and aryl, wherein at least one of R₃ and R₄ is H.

69. (Withdrawn) The method according to claim 67 wherein the substituent of R₁ and R₂ that is other than H is a C₁₋₆ alkyl, a C₁₋₆ cycloalkyl, a C₁₋₆ alkenyl, a substituted C₁₋₆ alkyl, a substituted C₁₋₆ cycloalkyl, a substituted C₁₋₆ alkenyl, a substituted aryl, a nitrogen containing group, a S containing group, or a carboxy group having from 1-6 carbon atoms.

70. (Withdrawn) The method according to claim 68 wherein the substituent of R₁ and R₂ that is other than H is a C₁₋₆ alkyl, a C₁₋₆ cycloalkyl, a C₁₋₆ alkenyl, a substituted C₁₋₆ alkyl, a substituted C₁₋₆ cycloalkyl, a substituted C₁₋₆ alkenyl, a substituted aryl, a nitrogen containing group, a S containing group, or a carboxy group having from 1-6 carbon atoms.

71. (Withdrawn) The method according to claim 69 wherein the substituent of R₁ and R₂ that is other than H is a C₁₋₆ alkyl, a C₁₋₆ alkenyl, a nitrogen containing group, or a carboxy group having from 1-6 carbon atoms.

72. (Withdrawn) The method according to claim 70 wherein the substituent of R₁ and R₂ that is other than H is a C₁₋₆ alkyl, a C₁₋₆ alkenyl, a nitrogen containing group, or a carboxy group having from 1-6 carbon atoms.

73. (Withdrawn) The method according to claim 71 wherein the substituent of R₁ and R₂ that is other than H is a is selected from C₁₋₆ alkyl, C₁₋₆ alkenyl, NO₂, or a carboxy group having from 1-6 carbon atoms.

74. (Withdrawn) The method according to claim 72 wherein the substituent of R₁ and R₂ that is other than H is a is selected from C₁₋₆ alkyl, C₁₋₆ alkenyl, NO₂, or a carboxy group having from 1-6 carbon atoms.

75. (Withdrawn) The method according to claim 73 wherein the substituent of R₁ and R₂ that is other than H is a C₃ alkyl, a C₃ alkenyl, NO₂, or H₃CO.

76. (Withdrawn) The method according to claim 74 wherein the substituent of R₁ and R₂ that is other than H is a C₃ alkyl, a C₃ alkenyl, NO₂, or H₃CO.

77. (Currently amended) The method according to claim 67 wherein the substituent of R₁ and R₂ that is other than H is [[a]]an alkoxy group.

78. (Previously presented) The method according to claim 68 wherein the substituent of R₁ and R₂ that is other than H is a alkoxy group.

79. (Previously presented) The method according to claim 77 wherein the substituent of R₁ and R₂ that is other than H is a methoxy group.

80. (Previously presented) The method according to claim 78 wherein the substituent of R₁ and R₂ that is other than H is a methoxy group.

81. (Previously presented) The method according to claim 67 wherein the group A/ring B combination contains one or more alkoxy substituents.

82. (Previously presented) The method according to claim 68 wherein the group A/ring B combination contains one or more alkoxy substituents.

83. (Withdrawn) The method according to claim 67 wherein each of R₁ and R₂ is an alkoxy group.

84. (Withdrawn) The method according to claim 68 wherein each of R₁ and R₂ is an alkoxy group.

85. (Withdrawn) The method according to claim 83 wherein each of R₁ and R₂ is a methoxy group.

86. (Withdrawn) The method according to claim 85 wherein each of R₁ and R₂ is a methoxy group.

87. (Previously presented) The method according to claim 67 wherein at least one of R₃ and R₄ is H.

88. (Currently amended) The method according to ~~any one of claims~~ claim 68 wherein each of R₃ and R₄ is H.

89. (Currently amended) The method according to claim 67 wherein Y is -C(O)-.

90. (Currently amended) The method according to claim 68 wherein Y is -C(O)-.

91. (Currently amended) The method of claim 68 wherein the endocrine-dependent cancer is breast, ovarian, endometrial, or prostate cancer.

92. (Previously presented) The method of claim 91 wherein the endocrine-dependent cancer is breast cancer.

93. (Currently amended) A method of treating endocrine-dependent cancer comprising administering a non-oestrogenic sulphamate compound suitable for use as an inhibitor of oestrone sulphatase to a patient in need of treatment of endocrine-dependent cancer by a non-oestrogenic sulphamate compound ~~lacking oestrogenic activity~~, wherein the compound has one of Formulae VI - IX

	R ₁	R ₂	Formula
a)	n- CH ₂ CH ₂ CH ₃	H	VI
b)	H	n-CH ₂ CH ₂ CH ₃	
c)	n- CH ₂ CH ₂ CH ₃	n-CH ₂ CH ₂ CH ₃	

	R ₁	R ₂	Formula
a)	- CH ₂ CH=CH ₂	H	VII
b)	H	-CH ₂ CH=CH ₂	
c)	- CH ₂ CH=CH ₂	-CH ₂ CH=CH ₂	

		R ₁	R ₂	Formula VIII
	a)	H ₃ CO-	H	
	b)	H	H ₃ CO-	
	c)	H ₃ CO-	H ₃ CO-	


		R ₁	R ₂	Formula IX
	a)	-NO ₂	H	
	b)	H	-NO ₂	


94. (Currently amended) The method of claim 93 wherein the endocrine-dependent cancer is breast, ovarian, endometrial, or prostate cancer.


95. (Previously presented) The method of claim 94 wherein the endocrine-dependent cancer is breast cancer.

96. (Currently amended) A method of inhibiting steroid sulphatase activity comprising administering a non-oestrogenic sulphamate compound to a patient in need of inhibition of steroid sulphatase activity by a non-oestrogenic sulphamate compound, wherein the compound has one of Formulae VI - IX.

		R ₁	R ₂	Formula VI
	a)	n-CH ₂ CH ₂ CH ₃	H	
	b)	H	n-CH ₂ CH ₂ CH ₃	
	c)	n-CH ₂ CH ₂ CH ₃	n-CH ₂ CH ₂ CH ₃	

		R ₁	R ₂	Formula VII
a)	-	H		
	CH ₂ CH=CH ₂			
b)	H	-CH ₂ CH=CH ₂		

		R ₁	R ₂	Formula VIII
a)	H ₃ CO-	H		
b)	H	H ₃ CO-		
c)	H ₃ CO-	H ₃ CO-		

		R ₁	R ₂	Formula IX
a)	-NO ₂	H		
b)	H	-NO ₂		
c)	-NO ₂	-NO ₂		